التفاصيل البيبلوغرافية
| العنوان: |
Boron Neutron Capture Therapy (BNCT) Mediated by Maleimide-Functionalized Closo -Dodecaborate Albumin Conjugates (MID:BSA) for Oral Cancer: Biodistribution Studies and In Vivo BNCT in the Hamster Cheek Pouch Oral Cancer Model. |
| المؤلفون: |
Monti Hughes, Andrea, Goldfinger, Jessica A., Palmieri, Mónica A., Ramos, Paula, Santa Cruz, Iara S., De Leo, Luciana, Garabalino, Marcela A., Thorp, Silvia I., Curotto, Paula, Pozzi, Emiliano C. C., Kawai, Kazuki, Sato, Shinichi, Itoiz, María E., Trivillin, Verónica A., Guidobono, Juan S., Nakamura, Hiroyuki, Schwint, Amanda E. |
| المصدر: |
Life (2075-1729); Jul2022, Vol. 12 Issue 7, p1082-1082, 15p |
| مصطلحات موضوعية: |
BORON-neutron capture therapy, ORAL cancer, HAMSTERS, NEUTRON irradiation, CHEEK, SERUM albumin |
| مستخلص: |
Background: BNCT (Boron Neutron Capture Therapy) is a tumor-selective particle radiotherapy that combines preferential boron accumulation in tumors and neutron irradiation. Although p-boronophenylalanine (BPA) has been clinically used, new boron compounds are needed for the advancement of BNCT. Based on previous studies in colon tumor-bearing mice, in this study, we evaluated MID:BSA (maleimide-functionalized closo-dodecaborate conjugated to bovine serum albumin) biodistribution and MID:BSA/BNCT therapeutic effect on tumors and associated radiotoxicity in the hamster cheek pouch oral cancer model. Methods: Biodistribution studies were performed at 30 mg B/kg and 15 mg B/kg (12 h and 19 h post-administration). MID:BSA/BNCT (15 mg B/kg, 19 h) was performed at three different absorbed doses to precancerous tissue. Results: MID:BSA 30 mg B/kg protocol induced high BSA toxicity. MID:BSA 15 mg B/kg injected at a slow rate was well-tolerated and reached therapeutically useful boron concentration values in the tumor and tumor/normal tissue ratios. The 19 h protocol exhibited significantly lower boron concentration values in blood. MID:BSA/BNCT exhibited a significant tumor response vs. the control group with no significant radiotoxicity. Conclusions: MID:BSA/BNCT would be therapeutically useful to treat oral cancer. BSA toxicity is a consideration when injecting a compound conjugated to BSA and depends on the animal model studied. [ABSTRACT FROM AUTHOR] |
|
Copyright of Life (2075-1729) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder